JP2017210484A5 - - Google Patents

Download PDF

Info

Publication number
JP2017210484A5
JP2017210484A5 JP2017162282A JP2017162282A JP2017210484A5 JP 2017210484 A5 JP2017210484 A5 JP 2017210484A5 JP 2017162282 A JP2017162282 A JP 2017162282A JP 2017162282 A JP2017162282 A JP 2017162282A JP 2017210484 A5 JP2017210484 A5 JP 2017210484A5
Authority
JP
Japan
Prior art keywords
group
compound
cooh
hydrogen
oso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017162282A
Other languages
English (en)
Japanese (ja)
Other versions
JP6417003B2 (ja
JP2017210484A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017210484A publication Critical patent/JP2017210484A/ja
Publication of JP2017210484A5 publication Critical patent/JP2017210484A5/ja
Application granted granted Critical
Publication of JP6417003B2 publication Critical patent/JP6417003B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017162282A 2014-02-03 2017-08-25 化学療法剤としてのβ置換βアミノ酸および類似体 Active JP6417003B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461935246P 2014-02-03 2014-02-03
US61/935,246 2014-02-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016567477A Division JP6200603B2 (ja) 2014-02-03 2015-02-03 化学療法剤としてのβ置換βアミノ酸および類似体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018189332A Division JP2019023214A (ja) 2014-02-03 2018-10-04 化学療法剤としてのβ置換βアミノ酸および類似体

Publications (3)

Publication Number Publication Date
JP2017210484A JP2017210484A (ja) 2017-11-30
JP2017210484A5 true JP2017210484A5 (https=) 2018-03-22
JP6417003B2 JP6417003B2 (ja) 2018-10-31

Family

ID=52589758

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016567477A Active JP6200603B2 (ja) 2014-02-03 2015-02-03 化学療法剤としてのβ置換βアミノ酸および類似体
JP2017162282A Active JP6417003B2 (ja) 2014-02-03 2017-08-25 化学療法剤としてのβ置換βアミノ酸および類似体
JP2018189332A Withdrawn JP2019023214A (ja) 2014-02-03 2018-10-04 化学療法剤としてのβ置換βアミノ酸および類似体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016567477A Active JP6200603B2 (ja) 2014-02-03 2015-02-03 化学療法剤としてのβ置換βアミノ酸および類似体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018189332A Withdrawn JP2019023214A (ja) 2014-02-03 2018-10-04 化学療法剤としてのβ置換βアミノ酸および類似体

Country Status (16)

Country Link
US (5) US9394237B2 (https=)
EP (1) EP3102195B1 (https=)
JP (3) JP6200603B2 (https=)
KR (1) KR101900584B1 (https=)
CN (1) CN106163509B (https=)
AU (2) AU2015210638B2 (https=)
BR (1) BR112016017997A2 (https=)
CA (1) CA2938571C (https=)
DK (1) DK3102195T3 (https=)
ES (1) ES2896882T3 (https=)
IL (1) IL247099A0 (https=)
MX (1) MX2016010095A (https=)
NZ (1) NZ723940A (https=)
SG (2) SG10201710436WA (https=)
TW (1) TWI597260B (https=)
WO (1) WO2015117147A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160346240A1 (en) * 2014-02-03 2016-12-01 Quadriga Biosciences, Inc. Methods of chemotherapy using chemotherapeutic agents based on beta-substituted beta-amino acids and analogs
ES2896882T3 (es) 2014-02-03 2022-02-28 Quadriga Biosciences Inc Beta-aminoácidos beta sustituidos y análogos como agentes quimioterapéuticos
WO2015117146A1 (en) 2014-02-03 2015-08-06 Quadriga Biosciences, Inc. Beta-substituted gamma-amino acids and analogs as chemotherapeutic agents
CN108026026B (zh) 2015-08-03 2021-02-09 夸德里加生物科学公司 作为化疗剂的β-取代的β-氨基酸和类似物及其应用
CN109174181B (zh) * 2018-08-10 2021-05-25 华东师范大学 一种负载双功能离子液体介孔聚合物的制备及其应用
IL295825A (en) * 2020-02-28 2022-10-01 Kallyope Inc gpr40 agonists
WO2022147743A1 (en) * 2021-01-08 2022-07-14 Quadriga Biosciences, Inc. Pharmaceutical compositions of chemotherapeutic agents based on beta-substituted beta-amino acid derivatives
JP2024513227A (ja) 2021-04-05 2024-03-22 ハリア・セラピューティクス・インコーポレイテッド Nek7阻害剤
US12427124B1 (en) 2024-04-10 2025-09-30 Maxymune Therapeutics, Inc. Phenylalanine-based LAT1 inhibitors and uses thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235594A (en) 1962-04-02 1966-02-15 Frosst & Co Charles E N-acyl-alpha-amino acid amides
US3299104A (en) 1963-04-09 1967-01-17 Leo Ab Certain steroid nu-bis-(haloethyl)-carbamates
SE7707451L (sv) 1976-07-12 1978-01-13 Merck & Co Inc Ÿ2-/3.(2-(tiazolyl eller tiazolinyl)tio)fenyl/-alkan(eller-alken)syror
US4339443A (en) 1978-09-22 1982-07-13 Fbc Limited Compounds and compositions
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US5015644A (en) 1987-06-02 1991-05-14 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds
FR2688499B1 (fr) * 1992-03-10 1994-05-06 Rhone Poulenc Rorer Sa Procede de preparation de la beta-phenylisoserine et de ses analogues.
US5602278A (en) 1994-10-20 1997-02-11 Kirkpatrick; Lynn N-oxides and derivatives of chlorambucil for treating hypoxic tumor cells
DK0797575T3 (da) 1994-12-13 2004-02-16 Hoffmann La Roche Imidazolderivater som proteinkinase-inhibitorer, især EGF-R-tyrosinkinase
JP3163391B2 (ja) * 1995-03-07 2001-05-08 味の素株式会社 スチルベン誘導体及びそれを含有する制癌剤
TW334418B (en) * 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
US6172057B1 (en) 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6306909B1 (en) * 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
CN1131855C (zh) 1997-12-16 2003-12-24 沃尼尔·朗伯公司 1-取代-1-氨基甲基-环烷衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途
TWI244481B (en) 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB0018528D0 (en) 2000-07-27 2000-09-13 Photocure Asa Compounds
GB0103857D0 (en) 2001-02-16 2001-04-04 Avecia Ltd Preparation of chloromandelic acid
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2003018565A1 (en) 2001-08-29 2003-03-06 Chirologix Pharmaceuticals Inc. Method for synthesizing oxazinones
US20040087556A1 (en) 2002-11-06 2004-05-06 Lynn Kirkpatrick N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor
JP2004175692A (ja) 2002-11-25 2004-06-24 Fuso Pharmaceutical Industries Ltd 抗腫瘍剤
BR0317253A (pt) 2002-12-13 2005-11-01 Warner Lambert Co Derivados pregabalina para o tratamento da fibromialgia e outras patologias
KR20110097942A (ko) 2003-08-20 2011-08-31 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
WO2005044780A1 (ja) 2003-11-10 2005-05-19 Kyorin Pharmaceutical Co., Ltd. アミノカルボン酸誘導体とその付加塩及びs1p受容体調節剤
EP2371815A1 (en) 2003-12-30 2011-10-05 XenoPort, Inc. Sythesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
JP4906715B2 (ja) 2004-05-08 2012-03-28 ニューロジェン・コーポレーション 4,5−ジ置換−2−アリールピリミジン類
US20060223866A1 (en) 2004-08-13 2006-10-05 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
CA2581426A1 (en) 2004-09-24 2006-04-06 Janssen Pharmaceutica, N.V. Sulfonamide compounds
EP1904078A4 (en) * 2005-05-12 2009-09-02 Attenuon Llc TREATMENT OF INFLAMMATORY DARMER DISEASES WITH ANTIANGIOGENIC COMPOUNDS
CA2609900A1 (en) * 2005-05-12 2006-11-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acti Ng For And On Behalf Of Arizona State University Stilbene derivatives and methods of inhibiting cancer cell growth and microbial growth
US20100144681A1 (en) 2005-08-11 2010-06-10 Klaus Fuchs Compounds for the treatment of alzheimer's disease
CA2618513A1 (en) 2005-08-11 2007-02-22 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
TWI328730B (en) 2006-06-16 2010-08-11 Ablerex Electronics Co Ltd Maximum power point tracking method and tracker thereof for a solar power system
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
US20080045534A1 (en) 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
EP1900729A1 (en) 2006-09-15 2008-03-19 Novartis AG Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors
WO2008088690A2 (en) 2007-01-12 2008-07-24 Merck & Co., Inc. A process for preparing diazabicyclo[3.3.1] nonane compounds
GB0705656D0 (en) 2007-03-23 2007-05-02 Addex Pharmaceuticals Sa Novel compounds E1
EP2217564A1 (en) 2007-09-07 2010-08-18 XenoPort, Inc. Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
TWI468375B (zh) 2008-10-27 2015-01-11 Janssen Pharmaceutica Nv 製備經保護之l-丙胺酸衍生物之方法
CN102282129A (zh) 2009-01-19 2011-12-14 雅培制药有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
US8344028B2 (en) 2009-04-17 2013-01-01 Xenoport, Inc. Gamma-amino-butyric acid derivatives as GABAB receptor ligands
UY32571A (es) 2009-04-24 2010-11-30 Glaxo Group Ltd Compuestos derivados de pirazol amida
CN102030683B (zh) 2009-09-27 2013-07-31 浙江九洲药业股份有限公司 西他列汀中间体及其制备方法和用途
AU2011281134B2 (en) 2010-07-23 2015-05-14 Connexios Life Sciences Pvt. Ltd. Agonists of GPR40
KR102507287B1 (ko) 2011-09-02 2023-03-07 인사이트 홀딩스 코포레이션 Pi3k 억제제로서 헤테로시클릴아민
KR101352635B1 (ko) 2011-12-29 2014-01-20 연세대학교 산학협력단 신규 혈관누출 차단제
DK2746250T3 (en) 2012-12-21 2018-01-02 Abx Advanced Biochemical Compounds Gmbh Intermediates and Processes for Preparation of 18F-Labeled Amino Acids
US20150353542A1 (en) 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
ES2896882T3 (es) * 2014-02-03 2022-02-28 Quadriga Biosciences Inc Beta-aminoácidos beta sustituidos y análogos como agentes quimioterapéuticos
CN108026026B (zh) 2015-08-03 2021-02-09 夸德里加生物科学公司 作为化疗剂的β-取代的β-氨基酸和类似物及其应用

Similar Documents

Publication Publication Date Title
JP2017210484A5 (https=)
JP2019034943A5 (https=)
JP2006143746A5 (https=)
JP2018529687A5 (https=)
JP2015024998A5 (https=)
JP2010511063A5 (https=)
JP2007503202A5 (https=)
JP2009543795A5 (https=)
JP2010526146A5 (https=)
JP2018534286A5 (https=)
JP2016534063A5 (https=)
JP2010520851A5 (https=)
JP2013515752A5 (https=)
JP2008510762A5 (https=)
JP2010534246A5 (https=)
JP2011525192A5 (https=)
JP2020507589A5 (https=)
JP2008500999A5 (https=)
JP2016514699A5 (https=)
JP2011518811A5 (https=)
JP2019535723A5 (https=)
JP2019516739A5 (https=)
JP2008520662A5 (https=)
JP2019519593A5 (https=)
JP2010521516A5 (https=)